Last reviewed · How we verify
PeerNaija: A Mobile Health Platform Incentivizing Medication Adherence Among Youth Living With HIV in Nigeria
NA trial testing PeerNaija in HIV/AIDS in 54 participants. Completed in 31 March 2024.
| Lead sponsor | Vanderbilt University Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 54 |
| Start date | 1 August 2021 |
| Primary completion | 13 March 2024 |
| Estimated completion | 31 March 2024 |
| Sites | 2 locations across Nigeria |
Vanderbilt University Medical Center
Adults 16 to 27, any sex, with HIV/AIDS. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Recruitment rate is measured by the percentage of participants randomized relative to total trial referrals.
| Group | Value | 95% CI |
|---|---|---|
| Social Incentive | 26 | |
| Social Plus Financial Incentive | 28 |
Retention rate is measured by the percentage of participants who completed the 24-week follow-up.
| Group | Value | 95% CI |
|---|---|---|
| Social Incentive | 19 | |
| Social Plus Financial Incentive | 23 |
Feasibility will be assessed with the Feasibility of Intervention Measure (FIM), a validated, four-item measure to determine the extent to which stakeholders believe an intervention is feasible to implement. The FIM will assess participant's likes/dislikes of the mobile health platform, privacy/security concerns, technology barriers, usage preferences, medication compliance and reasons for non-compliance. The FIM is scored on a scale of 1-5 with higher scores indicating higher perceived feasibility.
| Group | Value | 95% CI |
|---|---|---|
| Social Incentive | 4.0 | ± 0.7 |
| Social Plus Financial Incentive | 4.0 | ± 0.7 |
Acceptability will be assessed with the Acceptability of Intervention Measure (AIM), a validated, four-item measure to determine the extent to which stakeholders believe an intervention is feasible to implement. The AIM will assess participant's likes/dislikes of the mobile health platform, privacy/security concerns, technology barriers, usage preferences, medication compliance and reasons for non-compliance. The AIM is scored on a scale of 1-5 with higher scores indicating higher perceived acceptability.
| Group | Value | 95% CI |
|---|---|---|
| Social Incentive | 4.2 | ± 0.6 |
| Social Plus Financial Incentive | 4.0 | ± 0.7 |
Appropriateness will be assessed with the Intervention Appropriateness Measure (IAM), a validated, four-item measure to determine the extent to which stakeholders believe an intervention is feasible to implement. The IAM will assess participant's likes/dislikes of the mobile health platform, privacy/security concerns, technology barriers, usage preferences, medication compliance and reasons for non-compliance.
| Group | Value | 95% CI |
|---|---|---|
| Social Incentive | 4.2 | ± 0.6 |
| Social Plus Financial Incentive | 4.0 | ± 0.8 |
Preliminary efficacy will be assessed by identifying the number of participants virally suppressed at study end (undetectable \< 1000 m/ml).
| Group | Value | 95% CI |
|---|---|---|
| Social Incentive | 16 | |
| Social Plus Financial Incentive | 18 |
The PEERNaija application will feature routine medication reminders, along with individual adherence monitoring with adherence scores, anonymized peer adherence scores (from peers attending the same clinic; social incentive), and a monthly lottery-based prize for youth with the highest adherence scores (financial incentive). The Investigators will recruit a cohort of 50 HIV-infected adolescents and young adults (AYA) to pilot the app and assess feasibility, acceptability, adoption, and preliminary efficacy of important clinical measures (including adherence and virologic suppression). The proposed study will provide important preliminary data for the role of mobile health (mHealth) platforms to harness and deliver social and financial incentives to promote adherence efforts, especially for vulnerable youth, and for a larger intervention trial evaluating this app among HIV-infected AYA in Nigeria.
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04930198.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing